Tamoxifen in Axillary Node-Negative Breast Cancer: Multisystem Benefits and Risks

References

• Kessler L, Feuer E J, Brown M L. Projections of the breast cancer burden to US women: 1990–2000. Prev Med 1991; 20: 170–182
   PubMed Web of Science ®Google Scholar
• White E, Lee C Y, Kristal A R. Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst 1990; 82: 1546–1552
   PubMed Web of Science ®Google Scholar
• Ingle J N. Assessing the risk of recurrence in breast cancer. N Engl J Med 1990; 322: 329–331
   PubMed Web of Science ®Google Scholar
• Love R R. Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects. J Clin Oncol 1989; 7: 803–815
   PubMed Web of Science ®Google Scholar
• Henderson I C. Adjuvant systemic therapy of early breast cancer. Breast Diseases, 2nd ed., JR Harris, S Hellman, IC Henderson. JB Lippincott, Philadelphia 1991; 456–461, Chapter 17
   Google Scholar
• Pritchard K I. Current status of adjuvant endocrine therapy for resectable breast cancer. Semin Oncol 1987; 14: 23–33
   PubMed Web of Science ®Google Scholar
• Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC). Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet 1987; 1: 171–175
   Google Scholar
• Fisher B, Constantino J, Redmond C. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 1989; 320: 479–484
   PubMed Web of Science ®Google Scholar
• Nolvadex Adjuvant Trial Organization (NATO). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: analyses at eight years. Br J Cancer 1988; 57: 608–611
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group. The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319: 1681–1692
   PubMed Web of Science ®Google Scholar
• Cummings F J, Eudey L, Gray R. Adjuvant tamoxifen vs. placebo in elderly women with node positive breast cancer: long-term followup and causes of death. Proc Am Soc Clin Oncol 1991; 10: 44, (abstr51)
   Google Scholar
• Wolmark M. 1989: the year of adjuvant therapy in node negative breast cancer. Principles Prac Oncol Updates 1989; 3(12)9
   Google Scholar
• Pollack M, Costantino J, Polydrenakos C. Effects of tamoxifen on serum insulin-like growth factor 1 levels in stage I breast cancer patients. J Natl Cancer Inst 1990; 82: 1693–1697
   PubMed Web of Science ®Google Scholar
• Osborne C K. Prognostic factors in breast cancer. Principles Prac Oncol Updates 1990; 4(3)3
   Google Scholar
• Rosner D, Lane W W. Should all patients with node-negative breast cancer receive adjuvant therapy. Cancer 1991; 68: 1482–1494
   PubMed Web of Science ®Google Scholar
• Gilchrist K W, Kalish L, Gould V E. Interobserver reproducibility of histopathologic features in stage II breast cancer. Breast Cancer Res Treat 1985; 5: 3
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Wickerham D L. Systemic therapy in patients with node-negative breast cancer. Ann Intern Med 1989; 111: 703–712
   PubMed Web of Science ®Google Scholar
• Abellof M D, Gray R, Tormey D C. A randomized comparison of CMFPT versus CMFPTH/VATHT and maintenance versus no maintenance tamoxifen in premenopausal, node-positive breast cancer patients. An ECOG study. Proc Am Soc Clin Oncol 1991; 10: 43, (abstr 47)
   Google Scholar
• Falkson H C, Gray R, Wolbert W H. Adjuvant trial of twelve cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer. An ECOG phase III study. J Clin Oncol 1990; 8: 599–607
   PubMed Web of Science ®Google Scholar
• Fisher B, Braun A, Wolmark H. Prolonging tamoxifen for primary breast cancer. Ann Intern Med 1987; 106: 649–654
   PubMed Web of Science ®Google Scholar
• Hug V, Thomas H, Clark J. Chemotherapy and hormonal therapy in combination. J Clin Oncol 1988; 6: 173–177
   PubMed Web of Science ®Google Scholar
• Love R R, Cameron L, Connell B. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151: 1842–1847
   PubMed Web of Science ®Google Scholar
• Love R R, Surawicz T S, Williams E C. Antithrombin III, fibrinogen and platelet number changes with adjuvant tamoxifen therapy. Arch Intern Med February, 1992; Vol 152
   Web of Science ®Google Scholar
• Fornander T, Cedarmark B, Mattson A. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989; 1: 117–120
   PubMed Web of Science ®Google Scholar
• Gau T. Letter to oncology physicians July 2, 1987
   Google Scholar
• Dragan Y P, Xu Y, Pitot H C. Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev Med 1991; 20: 15–26
   PubMed Web of Science ®Google Scholar
• Yager I D, Shi Y E. Synthetic estrogen and tamoxifen as promoters of hepatocarcinogenesis. Prev Med 1991; 20: 27–37
   PubMed Web of Science ®Google Scholar
• Prentice R. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Prev Med 1991; 20: 38–46
   PubMed Web of Science ®Google Scholar
• Clemmessen J. Statistical studies in the aetiology of malignant neoplasms. V. Trends and risks Denmark 1943–72. Acta Pathol Microbiol Scand, Section A 1977; 38–50, (Suppl 261)
   Google Scholar
• Langstaff S, Sigurdsson H, O'Keeffe M. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 1989; 25: 1805–1809
   PubMedGoogle Scholar
• Kaiser-Kupfer M I, Lippman M E. Tamoxifen retinopathy. Cancer Treat Rep 1978; 62: 315–320
   PubMedGoogle Scholar
• Cummings S R, Black D M, Rubin S M. Lifetime risks of hip, Colles' or vertebral fracture, and coronary heart disease among white postmenopausal women. Arch Intern Med 1989; 149: 2445–2448
   PubMed Web of Science ®Google Scholar
• DeMets D L, Newcomb P A, Carey P. Design issues for a breast cancer chemoprevention trial. Prev Med 1991; 20: 101–108
   PubMed Web of Science ®Google Scholar
• Love R R. Antiestrogen chemoprevention of breast cancer: critical issues and research. Prev Med 1991; 20: 64–78
   PubMed Web of Science ®Google Scholar
• Baum M. Presentation at Progress and perspective in chemoprevention of cancer, MilanItaly, March 14, 1991
   Google Scholar
• Love R R, Wiebe D A, Newcomb P A. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860–864
   PubMed Web of Science ®Google Scholar
• McDonald C C, Stewart H J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 1991; 303: 435–437
   PubMed Web of Science ®Google Scholar
• Love R R, Mazess R B, Tormey D C. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988; 12: 297–301
   PubMed Web of Science ®Google Scholar
• Love R R, Mazess R B, Barden HS. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–856
   PubMed Web of Science ®Google Scholar